2023 Biopharma Predictions

Evaluate Vantage recently asked readers to anonymously provide their predictions for the upcoming year. The respondents, comprised of industry employees, investors, and bankers, speculated on everything from market conditions to M&A strategies. A key sticking point for many was the impending US drug pricing reforms implemented in the Inflation Reduction Act

According to Amy Brown, “Some noted that biotech is “uninvestable” unless new US laws around drug pricing, as part of the Inflation Reduction Act, change. Predictions in this area involved either complete reversal of IRA, or substantial strengthening – the status quo is presumably the consensus view here.”

To read more, click here.

(Source: Evaluate Vantage, December 23^rd, 2022)